Skip to content

Author

Marwa M. Qadri

We have 3 of 83 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Capivasertib Combination Therapy in Advanced Breast Cancer and Other Solid Tumors: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Biomarker-Defined Outcomes

Background: Capivasertib is an oral pan-AKT inhibitor evaluated in combination with multiple systemic therapies across solid tumors, but its efficacy and safety vary by disease setting, biomarker status, and treatment backbone. We aimed to systematically evaluate the efficacy, safety, and early-phase clinical activity...

Moudi M. Alasmari, Rana M. Aldossari, M. Aldriwesh et al. · 0 citations
Aug 2026

Remogliflozin Attenuates Thioacetamide-Induced Nephrotoxicity: Association with Nrf2/HO-1, SIRT1/AMPK, and TLR4/NF-κB Pathway Modulation.

In this exploratory model, remogliflozin was associated with attenuation of TAA-induced renal injury and modulation of related biomarkers, and warrants further preclinical investigation in TAA-associated renal injury.

Marwa M. Qadri, D. Almarghalani, Abdulaziz Alarifi et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.